You are here

Btk inhibitors

EHA 2019 – turnaround puts Arqule in the takeover frame

EHA 2019 – turnaround puts Arqule in the takeover frame

EP Vantage

Flag link:

Imbruvica resistance provides early but fertile development ground

Imbruvica resistance provides early but fertile development ground

EP Vantage

drug development

Flag link:

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Endpoints

Flag link:

In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle

In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle

Endpoints

autoimmune disease

Flag link:

$690M deal in peril after Lilly ends mid-stage studies

$690M deal in peril after Lilly ends mid-stage studies

Biopharma Dive

clinical trials

rheumatoid arthritis

Hanmi Pharmaceutical

LY3337641/HM71224

Flag link:

Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib

Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib

Endpoints

Flag link:

MannKind Rents Out a Drug Program

MannKind Rents Out a Drug Program

Motley Fool

Flag link:

Pharmacyclics Scores Big With Janssen Biotech Deal

Pharmacyclics Scores Big With Janssen Biotech Deal

Seeking Alpha

Janssen Biotech

Flag link: